Skip to main content
. 2022 Jul 12;22:760. doi: 10.1186/s12885-022-09864-y

Table 1.

Correlation of serum POSTN levels and clinicopathological characteristics of participants

Characteristics Number (%) POSTN(ng/mL) Mean ± SD P value
Health controls
Age (median) 52.1
   > 60 24 (34.8) 11.18 ± 5.51
   ≤ 60 45 (65.2) 12.29 ± 11.83 0.30a
Menopausal status
  Yes 43 (62.3) 11.79 ± 9.48
  No 26 (37.7) 11.21 ± 5.64 0.63a
Family history
  Yes 2 (2.9) 11.57 ± 8.31
  No 67 (97.1) 11.34 ± 3.65 -
Body mass index (BMI)
   < 24 42 (60.9) 11.31 ± 9.62
   ≥ 24 27 (39.1) 11.97 ± 5.44 0.18a
Breast cancer
Age (median) 50.6
   > 60 50 (28.9) 25.91 ± 16.52
   ≤ 60 123 (71.1) 31.18 ± 39.83 0.39a
Menopausal status
  Yes 109 (63.0) 29.27 ± 30.35
  No 64 (37.0) 30.31 ± 41.47 0.11a
Family history
  Yes 12 (6.9) 25.30 ± 11.50
  No 161 (93.1) 29.98 ± 35.90 0.42a
Body mass index (BMI)
   < 24 109 (63.0) 23.04 ± 20.88
   ≥ 24 64 (37.0) 40.93 ± 48.44 0.017a
TNM stage
  Locoregional BCa (I—IIIA) 115 (66.5) 20.03 ± 18.15
  Distant BCa IV (IIIB—IV) 58 (33.5) 48.73 ± 49.30  < 0.0001a
Lymph node metastasis
  Yes 94 (54.3) 36.83 ± 41.78
  No 79 (45.7) 21.12 ± 21.17 0.0002a
Distant metastasis
  Yes 36 (20.8) 56.33 ± 54.48
  No 137 (79.2) 22.65 ± 22.95  < 0.0001a
Metastasis site
  Multiple sites 17 (47.2)c 66.90 ± 61.64
  Single site 19 (52.8)c 46.88 ± 46.85 0.24a
  Bone 10 (27.8)c 47.76 ± 58.02
  Lung 5 (13.9)c 64.69 ± 35.28
  Liver 3 (8.3)c 26.53 ± 8.51
  Brain 1 (2.8)c 10.97
Molecular subtype
  Luminal A 66 (38.2) 30.92 ± 34.17
  Luminal B 60 (34.7) 26.75 ± 27.03
  Her2-enriched 18 (10.4) 37.94 ± 52.33
  Triple negative 29 (16.7) 27.64 ± 37.97 0.81b

a Mann–Whitney U test. b Kruskal–Wallis test. c Proportion in cases with distant metastasis